JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease

Johnson & Johnson (JNJ) announced that the FDA has granted a Fast Track designation ("FTD') to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren's disease ("SjD"), a chronic autoimmune disease. Currently, there are no advanced therapies approved by the FDA for the given indication. The Fast Track designation from the FDA facilitates rapid development and expedites the review of drug candidates that are being developed to treat serious conditions and for which ...